Truist lowered the firm’s price target on Inspire Medical to $260 from $340 and keeps a Buy rating on the shares as part of a broader research note on MedTech. The sector continues to trade down on fear of exposure to GLP-1s, and even good Q3 earnings may not matter amid a GLP-1 sector overhang, the analyst tells investors in a research note. While Truist continues to believe that the dramatic GLP1-driven sector pullback is likely overdone and that “narrative” is driving indiscriminate selling more so than a tangible fundamental impact, it’s hard to say when/if the GLP-1 overhang will subside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- Inspire Medical Systems, Inc. to Report Third Quarter 2023 Financial Results on November 7, 2023
- Inspire Medical Systems, Inc. Announces Events at International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings
- Weight-loss drugs are bad news for medtech makers, Barron’s says
- Inspire Medical price target lowered to $322 from $405 at UBS
- 3 Best Stocks to Buy Now, 8/25/2023, According to Top Analysts